Major hurdles, novel technologies and innovating autologous therapies
What are the biggest bottlenecks or hurdles that you have experienced with your cell therapy program?
Top 3 Responses:
Supply Chain
Manufacturing and CDMOs
Finances & Cost
Supply chain bottlenecks are the most common hurdle that cell therapy professionals have experienced with their programs.
Selected responses:
"Speed of pre-clinical development and regulatory considerations"
"Getting into the queue for having plasmids and vectors produced"
"The challenges of working with an outside party to schedule and facilitate improvements to our manufacturing process"
"Manufacturing site planning, build-out, and qualification"
Which next generation cell or gene therapy innovations or technologies are you likely to adopt?
Gene editing/CRISPR
Automated process systems
iPSCs
In response to this open question, gene editing and CRISPR technologies is the top innovation that respondents say that their companies are most likely to adopt. Automated process systems are the next most popular suggestion.
"Migration to full automation"
"Allogeneic MSCs and possibly iPS cells for dogs"
"Non-viral gene editing"
"Online monitoring and rapid testing"
"Acoustofluidic technologies in the bioprocessing"
"CRISPR/Cas9"
62% of respondents say they are definitely likely to develop their autologous cell therapy program to support a bedside setting.
